Summary

Asia-Pacific Cancer Biomarker Testing Market Research Report by Type (Product and Services), by Testing Type (Single Gene Testing and Multiple Gene Testing), by Region (China, India, Japan, South Korea, Singapore, Australia, New Zealand, Hong Kong, Thailand, and Taiwan) Forecast to 2032

Market Overview
Asia-Pacific Cancer the biomarker testing market is expected to grow at a significant CAGR of 12.58% during the review period.
Cancer biomarker testing uses biological markers such as chemicals or genes found in blood, tissues, or other physiological fluids to identify the presence, progression, or risk of cancer. These biomarkers can provide vital insights into a tumor's genetic, genomic, and cellular characteristics, allowing for early detection, diagnosis, prognosis, and treatment selection. Biomarker testing helps clinicians discover the specific characteristics of a patient's cancer, allowing for more individualised treatment plans. Biomarkers in cancer might be genetic (e.g., DNA mutations), proteomic (protein-related), or epigenetic. NGS, PCR, and immunohistochemistry are some of the testing methods used. Cancer biomarker testing is particularly beneficial for targeted therapies and immunotherapies because it identifies patients who are most likely to benefit from specific treatments based on the genetic makeup of their tumours. Biomarker testing not only guides medicine but also serves to monitor disease progression, detect recurrences, and assess therapy response. As cancer research advances, biomarker testing becomes a more significant tool for improving cancer care outcomes and fostering precision medicine.

Market Segmentation
The Asia-Pacific cancer biomarker testing market is divided into two segments: products and services. The product category dominated the market in 2023, while the services sector is expected to grow the fastest over the forecast period (2024-2032).
The Asia-Pacific cancer biomarker testing market is divided into two segments based on testing type: single gene and multiple gene. The multiple gene testing category dominated the market in 2023 and is expected to expand the quickest over the forecast period (2024-2032).
The global Asia-Pacific Cancer biomarker testing market is divided into the following countries: China, India, Japan, South Korea, Singapore, Australia, New Zealand, Hong Kong, Thailand, and Taiwan. The China sector had the greatest market share in 2023, while India is the fastest-growing segment throughout the projection period (2024-2032).
Major Players
F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Pacific Biosciences, Qiagen N.V., and Oxford Nanopore Technologies Plc. are the market's leading companies.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 EXECUTIVE SUMMARY 16
2 MARKET INTRODUCTION 18
2.1 DEFINITION 18
2.2 SCOPE OF THE STUDY 18
2.3 RESEARCH OBJECTIVE 18
2.4 MARKET STRUCTURE 19
3 RESEARCH METHODOLOGY 20
3.1 OVERVIEW 20
3.2 DATA FLOW 22
3.2.1 Data Mining Process 22
3.3 PURCHASED DATABASE: 23
3.4 SECONDARY SOURCES: 24
3.4.1 Secondary Research data flow: 25
3.5 PRIMARY RESEARCH: 26
3.5.1 Primary Research Data Flow: 27
3.5.2 Primary Research: Number of Interviews conducted 28
3.6 APPROACHES FOR MARKET SIZE ESTIMATION: 29
3.6.1 Revenue Analysis Approach 29
3.7 DATA FORECASTING 30
3.7.1 Data forecasting Type 30
3.8 DATA MODELING 31
3.8.1 microeconomic factor analysis: 31
3.8.2 Data modeling: 32
3.9 TEAMS AND ANALYST CONTRIBUTION 34
4 MARKET DYNAMICS 36
4.1 INTRODUCTION 36
4.2 DRIVERS 37
4.2.1 Growing Prevalence of Cancer 37
4.2.2 Rising Demand for Early Detection 37
4.2.3 Partnership Associated With Cancer Biomarker Testing Products 37
4.3 RESTRAINTS 38
4.3.1 Limited Access to Healthcare Infrastructure 38
4.3.2 High Cost OF Cancer Biomarker Testing 38
4.4 OPPORTUNITY 39
4.4.1 Growing Geriatric Population 39
4.4.2 Growing investment Associated with Cancer Biomarker Diagnosis 40
4.4.3 Ongoing Research to Develop Biomarker for Early Detection 40
5 MARKET FACTOR ANALYSIS 41
5.1 PORTER'S FIVE FORCES MODEL 41
5.1.1 Threat of New Entrants 41
5.1.2 Bargaining Power of Suppliers 42
5.1.3 Threat of Substitutes 42
5.1.4 Bargaining Power of Buyers 42
5.1.5 Intensity of Rivalry 43
5.2 IMPACT OF COVID-19 ON ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET 43
5.3 QUALITATIVE ANALYSIS FOR PROGRESSION & RESISTANCE PROFILING FOR CANCER 45
5.4 QUALITATIVE DATA ON THE TYPES OF DIGITAL SERVICES UTILIZED IN CANCER BIOMARKER TESTING 47
5.5 QUALITATIVE DATA ON TREATMENT SELECTION FOR TYPE OF CANCERS 48
6 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, BY TYPE 51
6.1 INTRODUCTION 51
6.2 PRODUCTS 54
6.3 SERVICES 55
7 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, BY TESTING TYPE 56
7.1 INTRODUCTION 56
7.2 SINGLE GENE TESTING 61
7.3 MULTIPLE GENE TESTING 62
8 ASIA-PACIFIC CANCER BIOMARKER TESTING MARKET, BY COUNTRY 63
8.1 OVERVIEW 63
8.1.1 India 67
8.1.2 Australia 71
8.1.3 Hong Kong 75
8.1.4 Taiwan 79
8.1.5 China 83
8.1.6 South Korea 87
8.1.7 Thailand 91
8.1.8 Japan 95
8.1.9 Singapore 99
8.1.10 New Zealand 103
9 COMPETITIVE LANDSCAPE 108
9.1 INTRODUCTION 108
9.2 MARKET SHARE ANALYSIS, 2023 108
9.3 COMPETITOR DASHBOARD 109
9.4 PUBLIC PLAYERS STOCK SUMMARY 110
9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL 110
9.1 KEY DEVELOPMENTS & GROWTH STRATEGIES 111
9.1.1 PRODUCT LAUNCH 111
9.1.2 PRODUCT APPROVAL 111
9.1.3 COLLABORATION 112
10 COMPANY PROFILES 113
10.1 F. HOFFMANN-LA ROCHE LTD. 113
10.1.1 COMPANY OVERVIEW 113
10.1.2 FINANCIAL OVERVIEW 114
10.1.3 PRODUCTS OFFERED 115
10.1.4 KEY DEVELOPMENTS 115
10.1.5 SWOT ANALYSIS 116
10.1.6 KEY STRATEGIES 116
10.2 THERMO FISHER SCIENTIFIC INC. 117
10.2.1 COMPANY OVERVIEW 117
10.2.2 FINANCIAL OVERVIEW 118
10.2.3 PRODUCTS OFFERED 118
10.2.4 KEY DEVELOPMENTS 119
10.2.5 SWOT ANALYSIS 120
10.2.6 KEY STRATEGIES 120
10.3 BIO-RAD LABORATORIES, INC. 121
10.3.1 COMPANY OVERVIEW 121
10.3.2 FINANCIAL OVERVIEW 122
10.3.3 PRODUCTS OFFERED 122
10.3.4 KEY DEVELOPMENTS 123
10.3.5 SWOT ANALYSIS 123
10.3.6 KEY STRATEGIES 124
10.4 ILLUMINA, INC. 125
10.4.1 COMPANY OVERVIEw 125
10.4.2 FINANCIAL OVERVIEW 126
10.4.3 PRODUCTS OFFERED 126
10.4.4 KEY DEVELOPMENTS 127
10.4.5 KEY STRATEGIES 127
10.5 PACIFIC BIOSCIENCES 128
10.5.1 COMPANY OVERVIEW 128
10.5.2 fINANCIAL OVERVIEW 129
10.5.3 PRODUCTS OFFERed 129
10.5.4 KEY DEVELOPMENTS 130
10.5.5 KEY STRATEGIES 130
10.6 GENEWIZ, INC. 131
10.6.1 COMPANY OVERVIEW 131
10.6.2 FINANCIAL OVERVIEW 132
10.6.3 SERVICES OFFERED 132
10.6.4 KEY DEVELOPMENTS 132
10.6.5 SWOT ANALYSIS 133
10.6.6 KEY STRATEGIES 133
10.7 QIAGEN N.V. 134
10.7.1 COMPANY OVERVIEW 134
10.7.2 FINANCIAL OVERVIEW 135
10.7.3 PRODUCTS OFFERed 135
10.7.4 KEY DEVELOPMENTS 136
10.7.5 SWOT ANALYSIS 137
10.7.6 KEY STRATEGIES 137
10.8 OXFORD NANOPORE TECHNOLOGIES PLC 138
10.8.1 COMPANY OVERVIEW 138
10.8.2 FINANCIAL OVERVIEW 139
10.8.3 PRODUCTS OFFERED 139
10.8.4 KEY DEVELOPMENTS 140
10.8.5 KEY STRATEGIES 140
10.9 MGI TECH CO., LTD. 141
10.9.1 COMPANY OVERVIEW 141
10.9.2 FINANCIAL OVERVIEW 141
10.9.3 PRODUCTS OFFERED 141
10.9.4 KEY DEVELOPMENTS 142
10.9.5 KEY STRATEGIES 142
10.10 BIOSERVE 143
10.10.1 COMPANY OVERVIEW 143
10.10.2 FINANCIAL OVERVIEW 143
10.10.3 SERVICES OFFERED 143
10.10.4 KEY DEVELOPMENTS 144
10.10.5 KEY STRATEGIES 144
11 DATA CITATIONS 145